After several months, inflammatory disease medication Dupixent has finally reclaimed its spot atop the rankings for over-the-counter (OTC) and Rx brand marketing on TV. The Regeneron and Sanofi brand, ...

The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...

The FDA approval is still pending, creating uncertainty around the market acceptance and commercial success of Dupixent for treating bullous pemphigoid, which may affect investor confidence.

Dupixent also demonstrated superiority over ... GlobalData is the parent company of Pharmaceutical Technology. Despite the commercial success, tensions between Regeneron and Sanofi have escalated.

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also ...

Positive results from the ADEPT Phase II/III study indicate that Dupixent (dupilumab) may be effective in treating moderate-to-severe bullous pemphigoid (BP). The findings were presented at the 2025 ...

Dupixent remains in the running to become a ... but with biosimilars to Xolair looming it is uncertain about the commercial potential of the drug. It's waiting on the results of trials in addition ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent (dupilumab) in adults ...